| The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients. | |
| | |
MedLine Citation:
|
PMID: 11862965 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The objective of this study was to compare the inflammatory marker eosinophil cationic protein (ECP) with peak expiratory flow (PEF) in determining the therapeutic needs of inhaled corticosteroids in asthma patients assessed as asthma symptoms. A randomized, single-blind study over 6 months was performed at six specialist centres in Europe. In total, 164 adult patients with moderate to severe symptomatic asthma and regular use of inhaled corticosteroids were included. After a run-in period of 2 weeks patients were randomly allocated to the ECP or the PEF monitoring group. The dose of inhaled cort costeroids was adjusted every fourth week based on the current serum ECP value or pre-bronchodilator morning PEF values as surrogate markers of therapeutic needs. At the end of the study there were no statistically significant differences in the mean daily symptom score or the percentage of symptom-free days between the two groups. The mean daily dose of inhaled corticosteroids was similar in the two groups at the start of the study but the algorithms used to adjust the dose of inhaled corticosteroids resulted in an increased use of inhaled corticosteroids in both groups. The mean daily dose of inhaled corticosteroids over the whole study period was significantly lower in the ECP group compared withthe PEF group (1246 vs. 1667 microg, P = 0.026). In the ECP group, forced expiratory volume in I sec (FEV)% predicted was lower at the end ofthe study compared with the begining (92% vs. 87%, P = 0 .0009), although there was no significant difference between the two groups. None of the used algorithms for ECP and PEF led to improvement in symptom scores, in spite of increased doses of inhaled corticosteroids. In this respect, both methods were equivalent and insufficient. Recommendations suggesting lung function tests in current guidelines may be difficult to translate into clinical practice, however, a combination of inflammatory markers, lung function and symptoms may still improve asthma control. |
| | |
Authors:
|
O Löwhagen; A M Wever; M Lusuardi; G Moscato; W A De Backer; L Gandola; C F Donner; S Ahlstedt; L Larsson; S T Holgate |
Related Documents
:
|
14583955 - Heliox for nonintubated acute asthma patients. 15249465 - The local side effects of inhaled corticosteroids: current understanding and review of ... 8239245 - Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of... 8493625 - Effect of an oral potassium channel activator, brl 38227, on airway function and respon... 7950475 - Statistical methods for clinical trials. 6494365 - The clinical eeg and personality in mentally abnormal offenders. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Respiratory medicine Volume: 96 ISSN: 0954-6111 ISO Abbreviation: Respir Med Publication Date: 2002 Feb |
Date Detail:
|
Created Date: 2002-02-25 Completed Date: 2002-03-13 Revised Date: 2009-11-03 |
Medline Journal Info:
|
Nlm Unique ID: 8908438 Medline TA: Respir Med Country: England |
Other Details:
|
Languages: eng Pagination: 95-101 Citation Subset: IM |
Affiliation:
|
Asthma and Allergy Research Group, Sahlgrenska University Hospital, Gothenburg, Sweden. olle.lowhagen@lungall.gu.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Inhalation Administration, Topical Adult Analysis of Variance Anti-Inflammatory Agents / administration & dosage* Asthma / drug therapy*, immunology, physiopathology Biological Markers / blood Blood Proteins / analysis* Drug Administration Schedule Eosinophil Granule Proteins Eosinophils Female Glucocorticoids Humans Leukocyte Count Lung / physiopathology* Male Middle Aged Peak Expiratory Flow Rate Proportional Hazards Models Ribonucleases* Single-Blind Method Statistics, Nonparametric |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Biological Markers; 0/Blood Proteins; 0/Eosinophil Granule Proteins; 0/Glucocorticoids; EC 3.1.-/Ribonucleases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of small airways in lung disease.
Next Document: Splanchnic and mammary nitrogen metabolism by dairy cows fed dry-rolled or steam-flaked sorghum grai...